Cargando…

Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre

Objective: To report on the outcomes of magnetic resonance imaging (MRI)/ultrasonography (US)-fusion transperineal prostate (TP) biopsy at a tertiary medical centre in the Middle East including detection rate of clinically significant prostate cancer (csPCa), complications, and tolerability of the p...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Achkar, Adnan, Al-Mousawy, Mouhammad, Abou Heidar, Nassib, Moukaddem, Hisham, Hussein, Hero, Mouallem, Nadim, El-Hajj, Albert, Bulbul, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648043/
https://www.ncbi.nlm.nih.gov/pubmed/34881061
http://dx.doi.org/10.1080/2090598X.2021.1926727
_version_ 1784610720149667840
author El-Achkar, Adnan
Al-Mousawy, Mouhammad
Abou Heidar, Nassib
Moukaddem, Hisham
Hussein, Hero
Mouallem, Nadim
El-Hajj, Albert
Bulbul, Muhammad
author_facet El-Achkar, Adnan
Al-Mousawy, Mouhammad
Abou Heidar, Nassib
Moukaddem, Hisham
Hussein, Hero
Mouallem, Nadim
El-Hajj, Albert
Bulbul, Muhammad
author_sort El-Achkar, Adnan
collection PubMed
description Objective: To report on the outcomes of magnetic resonance imaging (MRI)/ultrasonography (US)-fusion transperineal prostate (TP) biopsy at a tertiary medical centre in the Middle East including detection rate of clinically significant prostate cancer (csPCa), complications, and tolerability of the procedure. Patients and methods: Between May 2019 and June 2020, 98 MRI/US-fusion TP biopsies were performed in the US suite using light sedation. All patients had pre-biopsy 3-T multiparametric MRI. Data on patient characteristics, PCa detection rate and complication rates were collected retrospectively. A Gleason score ≥3 + 4 was defined as csPCa. RESULTS: There were 98 patients, with a mean (SD) age of 65 (9.1) years, and a median (SD) prostate-specific antigen level prior to biopsy of 7.53 (12.97) ng/mL and prostate volume of 51 (31.1) mL. PCa was detected in 54 (55%) patients, with csPCa detected in 43 (44%). A total of 124 Prostate Imaging-Reporting and Data System (PI-RADS) 3–5 lesions were targeted. Grade Group ≥2 PCa was found in 35.5% of the targeted lesions. Random biopsies detected one csPCa Gleason score 3 + 4 in one patient with a negative target. None of the patients had post-biopsy haematuria or retention. Only one patient developed acute prostatitis requiring in-patient intravenous antibiotics. CONCLUSIONS: MRI/US-fusion TP biopsy has an adequate detection rate of csPCa with minimal complications and low infection rates after biopsy. This is one of the first TP biopsy series in the Middle East paving the way for wider adoption in the region. ABBREVIATIONS: AS: active surveillance; AUR: acute urinary retention; GG: Grade Group; IQR: interquartile range; mpMRI: multiparametric MRI; (cs)PCa: (clinically significant) prostate cancer; PI-RADS: Prostate Imaging-Reporting and Data System; TP: transperineal; US: ultrasonography; TRUS: transrectal Ultrasound guided.
format Online
Article
Text
id pubmed-8648043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86480432021-12-07 Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre El-Achkar, Adnan Al-Mousawy, Mouhammad Abou Heidar, Nassib Moukaddem, Hisham Hussein, Hero Mouallem, Nadim El-Hajj, Albert Bulbul, Muhammad Arab J Urol Research Article Objective: To report on the outcomes of magnetic resonance imaging (MRI)/ultrasonography (US)-fusion transperineal prostate (TP) biopsy at a tertiary medical centre in the Middle East including detection rate of clinically significant prostate cancer (csPCa), complications, and tolerability of the procedure. Patients and methods: Between May 2019 and June 2020, 98 MRI/US-fusion TP biopsies were performed in the US suite using light sedation. All patients had pre-biopsy 3-T multiparametric MRI. Data on patient characteristics, PCa detection rate and complication rates were collected retrospectively. A Gleason score ≥3 + 4 was defined as csPCa. RESULTS: There were 98 patients, with a mean (SD) age of 65 (9.1) years, and a median (SD) prostate-specific antigen level prior to biopsy of 7.53 (12.97) ng/mL and prostate volume of 51 (31.1) mL. PCa was detected in 54 (55%) patients, with csPCa detected in 43 (44%). A total of 124 Prostate Imaging-Reporting and Data System (PI-RADS) 3–5 lesions were targeted. Grade Group ≥2 PCa was found in 35.5% of the targeted lesions. Random biopsies detected one csPCa Gleason score 3 + 4 in one patient with a negative target. None of the patients had post-biopsy haematuria or retention. Only one patient developed acute prostatitis requiring in-patient intravenous antibiotics. CONCLUSIONS: MRI/US-fusion TP biopsy has an adequate detection rate of csPCa with minimal complications and low infection rates after biopsy. This is one of the first TP biopsy series in the Middle East paving the way for wider adoption in the region. ABBREVIATIONS: AS: active surveillance; AUR: acute urinary retention; GG: Grade Group; IQR: interquartile range; mpMRI: multiparametric MRI; (cs)PCa: (clinically significant) prostate cancer; PI-RADS: Prostate Imaging-Reporting and Data System; TP: transperineal; US: ultrasonography; TRUS: transrectal Ultrasound guided. Taylor & Francis 2021-07-14 /pmc/articles/PMC8648043/ /pubmed/34881061 http://dx.doi.org/10.1080/2090598X.2021.1926727 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
El-Achkar, Adnan
Al-Mousawy, Mouhammad
Abou Heidar, Nassib
Moukaddem, Hisham
Hussein, Hero
Mouallem, Nadim
El-Hajj, Albert
Bulbul, Muhammad
Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre
title Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre
title_full Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre
title_fullStr Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre
title_full_unstemmed Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre
title_short Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre
title_sort magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: initial experience at a middle eastern tertiary medical centre
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648043/
https://www.ncbi.nlm.nih.gov/pubmed/34881061
http://dx.doi.org/10.1080/2090598X.2021.1926727
work_keys_str_mv AT elachkaradnan magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT almousawymouhammad magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT abouheidarnassib magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT moukaddemhisham magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT husseinhero magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT mouallemnadim magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT elhajjalbert magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre
AT bulbulmuhammad magneticresonanceimagingultrasonographyfusiontransperinealprostatebiopsyforprostatecancerinitialexperienceatamiddleeasterntertiarymedicalcentre